$ATYR
aTyr Pharma Inc

2016 Q1 Form 10-Q Financial Statement

#000156459016019103 Filed on May 11, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q4 2015 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.120M $3.810M $2.330M
YoY Change 76.82% 125.44% 51.3%
% of Gross Profit
Research & Development $12.00M $12.67M $6.593M
YoY Change 82.01% 191.94% 50.25%
% of Gross Profit
Depreciation & Amortization $233.0K $230.0K $209.0K
YoY Change 11.48% 9.52% 2.96%
% of Gross Profit
Operating Expenses $16.12M $16.48M $8.922M
YoY Change 80.62% 173.35% 50.46%
Operating Profit -$16.12M -$8.922M
YoY Change 80.62% 50.46%
Interest Expense -$40.00K
YoY Change -84.62%
% of Operating Profit
Other Income/Expense, Net $28.00K -$149.0K
YoY Change -118.79% -8.59%
Pretax Income -$16.09M -$16.49M -$9.070M
YoY Change 77.4% 173.01% 48.93%
Income Tax
% Of Pretax Income
Net Earnings -$16.09M -$16.49M -$9.071M
YoY Change 77.35% 173.15% 48.88%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$9.521M -$9.700M -$5.634M
COMMON SHARES
Basic Shares Outstanding 23.68M 23.65M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q4 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $86.00M $95.54M $54.50M
YoY Change 57.8% 500.85%
Cash & Equivalents $54.10M $53.03M $54.51M
Short-Term Investments $31.90M $42.51M $0.00
Other Short-Term Assets $1.600M $2.400M $700.0K
YoY Change 128.57% 242.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $87.60M $97.95M $55.17M
YoY Change 58.78% 493.31%
LONG-TERM ASSETS
Property, Plant & Equipment $1.800M $1.793M $1.839M
YoY Change -2.12% -6.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $25.60M $29.80M
YoY Change
Other Assets $100.0K $118.0K $2.897M
YoY Change -96.55% -94.66%
Total Long-Term Assets $27.50M $31.73M $4.736M
YoY Change 480.66% 667.23%
TOTAL ASSETS
Total Short-Term Assets $87.60M $97.95M $55.17M
Total Long-Term Assets $27.50M $31.73M $4.736M
Total Assets $115.1M $129.7M $59.91M
YoY Change 92.14% 528.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.900M $3.872M $3.168M
YoY Change 86.24% 170.2%
Accrued Expenses $3.600M $4.595M $2.645M
YoY Change 36.11% 56.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.400M $3.366M $5.200M
YoY Change -34.62% -34.0%
Total Short-Term Liabilities $13.19M $12.15M $11.55M
YoY Change 14.26% 20.12%
LONG-TERM LIABILITIES
Long-Term Debt $900.0K $1.776M $4.300M
YoY Change -79.07% -65.18%
Other Long-Term Liabilities $557.0K $571.0K $380.0K
YoY Change 46.58% 70.45%
Total Long-Term Liabilities $557.0K $2.347M $380.0K
YoY Change 46.58% 600.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.19M $12.15M $11.55M
Total Long-Term Liabilities $557.0K $2.347M $380.0K
Total Liabilities $13.75M $14.50M $11.93M
YoY Change 15.29% 38.73%
SHAREHOLDERS EQUITY
Retained Earnings -$174.2M -$158.1M -$119.2M
YoY Change 46.12% 43.55%
Common Stock $274.7M $273.3M $21.22M
YoY Change 1194.6% 1322.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $100.4M $115.1M -$98.01M
YoY Change
Total Liabilities & Shareholders Equity $115.1M $129.7M $59.91M
YoY Change 92.18% 528.15%

Cashflow Statement

Concept 2016 Q1 2015 Q4 2015 Q1
OPERATING ACTIVITIES
Net Income -$16.09M -$16.49M -$9.071M
YoY Change 77.35% 173.15% 48.88%
Depreciation, Depletion And Amortization $233.0K $230.0K $209.0K
YoY Change 11.48% 9.52% 2.96%
Cash From Operating Activities -$12.49M -$9.840M -$6.290M
YoY Change 98.57% 69.66% -0.94%
INVESTING ACTIVITIES
Capital Expenditures $314.0K -$110.0K $123.0K
YoY Change 155.28% -41.71%
Acquisitions
YoY Change
Other Investing Activities $14.71M $4.020M $1.950M
YoY Change 654.36% 46.18% -136.11%
Cash From Investing Activities $14.39M $3.910M $1.830M
YoY Change 686.34% 42.18% -132.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $11.00K $69.00K
YoY Change -84.06% 430.77%
Debt Paid & Issued, Net $838.0K
YoY Change
Cash From Financing Activities -830.0K -1.090M 45.07M
YoY Change -101.84% -39.11% 450600.0%
NET CHANGE
Cash From Operating Activities -12.49M -9.840M -6.290M
Cash From Investing Activities 14.39M 3.910M 1.830M
Cash From Financing Activities -830.0K -1.090M 45.07M
Net Change In Cash 1.070M -7.020M 40.61M
YoY Change -97.37% 45.04% -439.83%
FREE CASH FLOW
Cash From Operating Activities -$12.49M -$9.840M -$6.290M
Capital Expenditures $314.0K -$110.0K $123.0K
Free Cash Flow -$12.80M -$9.730M -$6.413M
YoY Change 99.66% 67.76% -2.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129675000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
16115000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
8922000
CY2015Q4 us-gaap Long Term Investments
LongTermInvestments
29814000
CY2016Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
557000
CY2016Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
24000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
273321000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-171000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-158124000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
115050000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.39
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15935000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9071000
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
233000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
209000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4595000
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
13191000
CY2016Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
49000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
152000
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23631133
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23677303
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23670079
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23677303
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23670079
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
966322
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-9071000
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
24000
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
274638000
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-19000
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-174211000
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
100432000
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115125000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-16087000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3786103
CY2016Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2015Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1411000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1280000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
603000
CY2016Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
54000
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19728684
CY2015Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
123000
CY2016Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
9994000
CY2016Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
24700000
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1950000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
14392000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
1827000
CY2015Q1 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
795000
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
501000
CY2015Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
128000
CY2015Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-77000
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-264000
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-4000
CY2016Q1 life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-76000
CY2015Q1 life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-71000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-858000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
187000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
983000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
765000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12491000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6286000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
314000
CY2015Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
46299000
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
69000
CY2016Q1 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
838000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-827000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
45072000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1074000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
40613000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13899000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54512000
CY2015Q1 life Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
1233000
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Our consolidated financial statements are prepared in accordance with GAAP. The preparation of our consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes. The most significant estimates in our consolidated financial statements relate to the fair value of equity issuances and awards, and clinical trials and research and development expense accruals. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</p></div>
CY2016Q1 life Noncancelable Operating Leases Term Of Expiration
NoncancelableOperatingLeasesTermOfExpiration
2017-05
CY2011Q4 life Lease Agreement Extended Term
LeaseAgreementExtendedTerm
P5Y
CY2016Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
44136
CY2015Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
39439
CY2015Q2 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2000000
CY2015Q2 us-gaap Interest Paid
InterestPaid
500000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
461000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
231000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
692000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2625280
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1310569
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5144
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
314448
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3616257
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.83
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.21
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.06
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.28
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.04
CY2016Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6927216
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4766580

Files In Submission

Name View Source Status
0001564590-16-019103-index-headers.html Edgar Link pending
0001564590-16-019103-index.html Edgar Link pending
0001564590-16-019103.txt Edgar Link pending
0001564590-16-019103-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
life-10q_20160331.htm Edgar Link pending
life-20160331.xml Edgar Link completed
life-20160331.xsd Edgar Link pending
life-20160331_cal.xml Edgar Link unprocessable
life-20160331_def.xml Edgar Link unprocessable
life-20160331_lab.xml Edgar Link unprocessable
life-20160331_pre.xml Edgar Link unprocessable
life-ex311_9.htm Edgar Link pending
life-ex312_6.htm Edgar Link pending
life-ex321_10.htm Edgar Link pending
life-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending